CAPRICOR THERAPEUTICS, INC.(CAPR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CAPR Stock Analysis & AI Quality Score
AI stock analysis and institutional research for CAPRICOR THERAPEUTICS, INC. (CAPR), a Healthcare sector company. CAPR is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q4 2025), CAPRICOR THERAPEUTICS, INC. reports net income of $-30.2M, free cash flow of $-25.2M. Top institutional holders of CAPR by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, BlackRock,, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. CAPR trades on the Nasdaq exchange and files with the SEC under CIK 1133869. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CAPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CAPRICOR THERAPEUTICS, INC. directly from SEC EDGAR. CAPRICOR THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 5 and 24 since 2024, currently 4.8 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.
Net Income
Q4 2025
$-30.2M
Free Cash Flow
Q4 2025
$-25.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-100.0% YoYNet Income
-159.6% YoYOperating Income
-154.1% YoYEPS (Diluted)
-96.5% YoYTotal Assets
+108.8% YoYOp. Cash Flow
-74.5% YoY| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 -100.0% | $22.3M +772.8% | $2.6M +941.8% | $244.9K -21.1% | $310.3K -69.1% | $1.0M |
| Net Income | $-105.0M -159.6% | $-40.5M -39.4% | $-29.0M -44.9% | $-20.0M -46.6% | $-13.7M -78.7% | $-7.6M |
| Operating Income | $-108.1M -154.1% | $-42.6M -43.3% | $-29.7M -41.8% | $-20.9M -52.9% | $-13.7M -77.0% | $-7.7M |
| EPS (Diluted) | $-2.26 -96.5% | $-1.15 +2.5% | $-1.18 -35.6% | $-0.87 +1.1% | $-0.88 | — |
| Total Assets | $355.9M +108.8% | $170.5M +240.3% | $50.1M +21.2% | $41.3M +19.4% | $34.6M +211.5% | $11.1M |
| Operating Cash Flow | $-69.8M -74.5% | $-40.0M -913.5% | $4.9M +129.2% | $-16.8M -67.2% | $-10.1M -47.4% | $-6.8M |
Get alerted when CAPR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CAPRICOR THERAPEUTICS, INC. including:
Top Institutional Holders of CAPR
SUVRETTA CAPITAL MANAGEMENT, LLC
$116.1M3,818,600 shBlackRock, Inc.
$104.0M3,421,815 shTANG CAPITAL MANAGEMENT LLC
$103.4M3,399,900 shSTATE STREET CORP
$66.3M2,181,901 shVANGUARD CAPITAL MANAGEMENT LLC
$61.6M2,027,732 shRA CAPITAL MANAGEMENT, L.P.
$45.8M1,507,844 shGEODE CAPITAL MANAGEMENT, LLC
$34.0M1,118,326 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$32.0M1,051,800 shGOLDMAN SACHS GROUP INC
$27.7M911,976 shJones Hill Capital LP
$27.6M909,207 sh
| Fund | Value | Shares |
|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $116.1M | 3,818,600 |
| BlackRock, Inc. | $104.0M | 3,421,815 |
| TANG CAPITAL MANAGEMENT LLC | $103.4M | 3,399,900 |
| STATE STREET CORP | $66.3M | 2,181,901 |
| VANGUARD CAPITAL MANAGEMENT LLC | $61.6M | 2,027,732 |
| RA CAPITAL MANAGEMENT, L.P. | $45.8M | 1,507,844 |
| GEODE CAPITAL MANAGEMENT, LLC | $34.0M | 1,118,326 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $32.0M | 1,051,800 |
| GOLDMAN SACHS GROUP INC | $27.7M | 911,976 |
| Jones Hill Capital LP | $27.6M | 909,207 |
More Healthcare Companies
View all Healthcare →Put CAPR on your watchlist
Track score changes the day CAPRICOR THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CAPR a good stock to buy?
13F Pro's AI-powered analysis of CAPRICOR THERAPEUTICS, INC. (CAPR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CAPR are available on the CAPR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CAPR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CAPR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CAPRICOR THERAPEUTICS, INC.'s investment landscape.